Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03607487
Other study ID # INCB 54707-203
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 15, 2018
Est. completion date August 13, 2019

Study information

Verified date September 2022
Source Incyte Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety of INCB054707 over an 8-week treatment period in men and women with moderate to severe hidradenitis suppurativa.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date August 13, 2019
Est. primary completion date August 13, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Diagnosis of HS (confirmed by a dermatologist) with a disease duration of at least 6 months before screening. - Stable course of HS for at least 90 days before screening, as determined by the investigator. - HS lesions present in at least 2 distinct anatomic areas, 1 of which must be Hurley Stage II or Hurley Stage III at screening. - Total AN count of at least 3 at screening and baseline. - Willingness to avoid pregnancy or fathering children. Exclusion Criteria: - Women who are currently pregnant or lactating. - Presence of > 20 draining fistulas at screening and baseline. - Participants with protocol-defined concurrent conditions or history of other diseases. - Prolonged QT interval corrected for heart rate using Fridericia's formula (QTcF), defined as = 450 msec. - Positive test result for tuberculosis from the QuantiFERON-TB Gold test, or T-SPOT.TB test at screening. - A history of active tuberculosis (treated or untreated) or a history of untreated latent tuberculosis. - Positive serology test results for HIV, hepatitis B surface antigen, hepatitis B virus core antibody, or hepatitis C virus (HCV antibody with positive HCV-RNA) at screening. - Decreased blood cell counts at screening per protocol-defined criteria. - Severely impaired liver function (Child-Pugh Class C) or alanine aminotransferase or aspartate aminotransferase levels = 1.5 × upper limit of normal at screening. - Impaired renal function with serum creatinine > 1.5 mg/dL at screening. - Use of protocol-prohibited medications. - Known or suspected allergy to INCB054707 or any component of the study drug. - Known history of clinically significant drug or alcohol abuse in the last year before baseline.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
INCB054707
INCB054707 tablet administered orally once daily at the protocol-defined dose.
Placebo
Placebo tablet administered orally once daily.

Locations

Country Name City State
Canada Investigative Site Barrie Ontario
Canada Investigative Site Drummondville Quebec
Canada Investigative Site Fredericton New Brunswick
Canada Investigative Site London Ontario
Canada Investigative Site 009 Markham Ontario
Canada Investigative Site 008 Richmond Hill Ontario
Canada Investigative Site St-Jerome Quebec
Canada Investigative Site 007 Windsor Ontario
Canada Investigative Site Winnipeg Manitoba
Denmark Investigative Site Aarhus
Denmark Investigative Site Roskilde
Germany Investigative Site Bochum Noth Rhine-Westphalia
Germany Investigative Site Lübeck Schleswig-Holstein

Sponsors (1)

Lead Sponsor Collaborator
Incyte Corporation

Countries where clinical trial is conducted

Canada,  Denmark,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Treatment-emergent Adverse Events (TEAEs) TEAE is defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug. Grading was performed using guidance from the CTCAE v 4.03. A grade 3 and above would constitute as "severe". Up to 12 weeks
Secondary Apparent Oral Clearance of INCB054707 To determine the systemic exposure to INCB054707. Dependent upon the final compartmental model describing INCB054707. Predose Day 1, Week 4, and 8, Postdose Day1, week 2,4,6, and 8
Secondary Apparent Oral Volume of Distribution of INCB054707 To determine the systemic exposure to INCB054707. Dependent upon the final compartmental model describing INCB054707. Predose Day 1, Week 4, and 8, Postdose Day1, week 2,4,6, and 8
Secondary Proportion of Participants Achieving a Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit HiSCR defined as at least 50% reduction in abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline. Weeks 1, 2, 4, 6, 8, Early Termination and Follow-up (Up to 3 months)
Secondary Proportion of Participants Achieving an AN Count of 0 to 2 at Each Visit AN defined as abscess and inflammatory nodule count. Baseline,Weeks 1, 2, 4, 6, 8, Early Termination and Follow-up (Up to 3 months)
Secondary Mean Change From Baseline in the Hidradenitis Suppurativa Pain Numeric Rating Scale (HS Pain NRS) Scores at Each Visit An 11-point scale used to assess the worst skin pain and the average skin pain due to HS. Skin pain ranges from 0 ("no skin pain") to 10 ("skin pain as bad as you can imagine"). Baseline,Weeks 1, 2, 4, 6, 8, Early Termination and Follow-up (Up to 3 months)
Secondary Mean Change From Baseline in the Modified Sartorius Scale Score The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other). For each area, points are awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated buy normal skin (yes-0 point; no-6 points). The total Sartorius Scale score is the sum of the 12 regional scores. Scale scores range from 0 to infinite, with larger scores representing higher severity of HS. From baseline up to week 8
Secondary Mean Change From Baseline in the Number of Draining Fistulas Count at Each Visit. Defined as fistulas that drain serous or purulent fluid, either spontaneously or by gentle palpation. Baseline,Weeks 1, 2, 4, 6, 8 and Follow-up (Up to 3 months)
Secondary Proportion of Participants at Each Category of Hurley Stage The Hurley classification is a static score and was originally designed for selection of the appropriate treatment modality in a certain body region. The assessor determines the Hurley stage in each affected anatomical region. If more than 1 stage is present in the same region, the worst stage in that region is documented. The participant will be assigned an overall Hurley stage classification corresponding to the stage of the worst involved anatomical region. The definition of each Hurley stage is as follows:
Stage I : Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring).
Stage II : One or more widely separated recurrent abscesses with tract formation and cicatrization (scarring).
Stage III : Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.
Baseline and Week 8
Secondary Proportions of Participants in Each HS Patient Global Impression of Change (PGIC) Category During the Treatment Period The HS-PGIC consists of 1 self-administered item that assesses change in the severity of skin in the HS area. The participant will answer the following: Since your last visit, your HS is: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse, or (7) very much worse. Up to 12 weeks
Secondary Actual Measurements in HS-PGIC at Each Visit The HS-PGIC consists of 1 self-administered item that assesses change in the severity of skin in the HS area. The participant will answer the following: Since your last visit, your HS is: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse, or (7) very much worse. Up to 12 weeks
Secondary Proportion of Participants With Change From Baseline Hurley Stage The Hurley classification is a static score and was originally designed for selection of the appropriate treatment modality in a certain body region. The assessor determines the Hurley stage in each affected anatomical region. If more than 1 stage is present in the same region, the worst stage in that region is documented. The participant will be assigned an overall Hurley stage classification corresponding to the stage of the worst involved anatomical region. The definition of each Hurley stage is as follows:
Stage I : Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring).
Stage II : One or more widely separated recurrent abscesses with tract formation and cicatrization (scarring).
Stage III : Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.
Baseline and Week 8
See also
  Status Clinical Trial Phase
Completed NCT02904902 - Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa Phase 3
Completed NCT03628924 - A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Phase 2
Not yet recruiting NCT05531747 - Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa N/A
Recruiting NCT06028230 - A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Completed NCT03275870 - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Phase 1/Phase 2
Completed NCT03248531 - A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. Phase 2
Withdrawn NCT04100083 - Spironolactone for Hidradenitis Suppurativa Phase 4
Completed NCT00329823 - Etanercept in Hidradenitis Suppurativa Phase 2
Recruiting NCT05710393 - Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
Completed NCT04019041 - A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa Phase 2
Completed NCT05286567 - A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa. Phase 1
Withdrawn NCT03929835 - Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa Phase 2
Terminated NCT04325607 - Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa N/A
Terminated NCT03238469 - Microwave Ablation in Mild Axillary Hidradenitis Suppurativa N/A
Completed NCT04449354 - HidraWear AX HS Study N/A
Recruiting NCT06123429 - Mindfulness in Hidradenitis Suppurativa N/A
Recruiting NCT05934825 - Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa Phase 1/Phase 2
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting NCT06046729 - A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Recruiting NCT04246372 - Tofacitinib for Immune Skin Conditions in Down Syndrome Phase 2